SCHEMBL22490650

SCHEMBL22490650

Clc1cc(Cl)c2nccn2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
HTR3A P46098 1/20 0.41
NUDT1 P36639 1/20 0.39
EGLN2 Q96KS0 1/20 0.34
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA3 P42263 1/20 0.33
GRIA4 P48058 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
AURKA O14965 1/20 0.33
HTR2C P28335 1/20 0.32
TNKS O95271 1/20 0.32
GSK3B P49841 1/20 0.32
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14006669 0.82 NUDT1 (0.47) L3MBTL1HTR3ANUDT1AURKAGSK3B
SCHEMBL1983144 0.80 L3MBTL1 (0.49) L3MBTL1HTR3ANUDT1AURKAHTR2C
SCHEMBL3847774 0.80 L3MBTL1 (0.62) L3MBTL1HTR3ANUDT1GRIN2DGRIN3B
SCHEMBL25310547 0.80 NUDT1 (0.45) L3MBTL1HTR3ANUDT1GRIN2DGRIN3B
SCHEMBL25974824 0.80 L3MBTL1 (0.41) L3MBTL1HTR3ANUDT1AURKAHTR2C
Hydrochloric Acid SCHEMBL2420306 0.79 L3MBTL1 (0.47) L3MBTL1HTR3ANUDT1AURKAHTR2C
SCHEMBL6370588 0.77 L3MBTL1 (0.42) L3MBTL1HTR3ANUDT1AURKATNKS
SCHEMBL21439074 0.76 HTR3A (0.42) L3MBTL1HTR3ANUDT1AURKA
SCHEMBL3340580 0.76 SMN1; SMN2 (0.49) L3MBTL1NUDT1KMT2A
SCHEMBL24857368 0.76 L3MBTL1 (0.41) L3MBTL1HTR3ANUDT1AURKATNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667257-B Compounds for inhibiting CDK7 伊莱利利公司 2024-06-11 CN disclosed
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 ELI LILLY AND COMPANY 2023-06-29 US disclosed
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 ELI LILLY AND COMPANY 2023-06-29 US disclosed
US-11112366-B2 Reagent and kit for enhancing chemiluminescent reaction NATIONAL TAIWAN OCEAN UNIVERSITY (TW) 2021-09-07 US disclosed
US-20200309707-A1 REAGENT AND KIT FOR ENHANCING CHEMILUMINESCENT REACTION NATIONAL TAIWAN OCEAN UNIVERSITY (TW) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11112366-B2 Reagent and kit for enhancing chemiluminescent reaction MPO, LPO, KIT L3MBTL1 1502/4885HTR3A 3366/4885NUDT1 49/4885
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 CDK7, CDK3, CCNH L3MBTL1 3056/4885HTR3A 2963/4885NUDT1 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.